Myriad Genetics (MYGN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.98, -8.51% vs the prior close of $4.35.
- Volume 1.42M shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
MYGN slides 8.5% to $3.98. Closed at $3.98, -8.51% vs the prior close of $4.35. Day range $3.97–$4.34, opened at $4.34.
MYGN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — MYGN slides 8.5% to $3.98
- Closed at $3.98, -8.51% vs the prior close of $4.35. Day range $3.97–$4.34, opened at $4.34.
- Volume was 1.42M shares, 0.8x its 50-day average of 1.85M.
- Price is +8.6% vs its 50-day average ($3.67) and -14.1% vs its 200-day average ($4.63).
- 52-week range $2.74–$8.59; today's close sits at 21% of that range, 53.7% below the 52-week high.
Oct 15, 2026 — MYGN jumps 4.8% to $4.35
- Closed at $4.35, +4.82% vs the prior close of $4.15. Day range $4.11–$4.42, opened at $4.20.
- Volume was 1.07M shares, 0.6x its 50-day average of 1.90M — lighter than usual.
- Price is +19.2% vs its 50-day average ($3.65) and -6.3% vs its 200-day average ($4.64).
- 52-week range $2.74–$8.59; today's close sits at 28% of that range, 49.4% below the 52-week high.
Oct 14, 2026 — MYGN rises 1.7% to $4.15
- Closed at $4.15, +1.72% vs the prior close of $4.08. Day range $4.04–$4.29, opened at $4.08.
- Volume was 1.86M shares, 1.0x its 50-day average of 1.94M.
- Price is +14.5% vs its 50-day average ($3.63) and -10.8% vs its 200-day average ($4.65).
- 52-week range $2.74–$8.59; today's close sits at 24% of that range, 51.7% below the 52-week high.
Oct 13, 2026 — MYGN dips 2.9% to $4.08
- Closed at $4.08, -2.86% vs the prior close of $4.20. Day range $4.05–$4.22, opened at $4.20.
- Volume was 1.38M shares, 0.7x its 50-day average of 2.06M.
- Price is +13.1% vs its 50-day average ($3.61) and -12.5% vs its 200-day average ($4.66).
- 52-week range $2.74–$8.59; today's close sits at 23% of that range, 52.5% below the 52-week high.
Oct 12, 2026 — MYGN dips 2.6% to $4.20
- Closed at $4.20, -2.55% vs the prior close of $4.31. Day range $4.19–$4.32, opened at $4.30.
- Volume was 1.38M shares, 0.6x its 50-day average of 2.34M — lighter than usual.
- Price is +17.2% vs its 50-day average ($3.59) and -10.2% vs its 200-day average ($4.68).
- 52-week range $2.74–$8.59; today's close sits at 25% of that range, 51.1% below the 52-week high.
Oct 9, 2026 — MYGN rises 2.6% to $4.31
- Closed at $4.31, +2.62% vs the prior close of $4.20. Day range $4.15–$4.40, opened at $4.18.
- Volume was 1.37M shares, 0.6x its 50-day average of 2.36M — lighter than usual.
- Price is +21.1% vs its 50-day average ($3.56) and -8.1% vs its 200-day average ($4.69).
- 52-week range $2.74–$8.59; today's close sits at 27% of that range, 49.8% below the 52-week high.
- SEC filings that day: 8-K.
Oct 8, 2026 — MYGN dips 1.9% to $4.20, 3 down days in a row
- Closed at $4.20, -1.87% vs the prior close of $4.28. Day range $4.05–$4.26, opened at $4.24.
- Volume was 2.26M shares, 1.0x its 50-day average of 2.34M.
- Price is +17.3% vs its 50-day average ($3.58) and -10.6% vs its 200-day average ($4.70).
- 52-week range $2.74–$8.59; today's close sits at 25% of that range, 51.1% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — MYGN ends flat (+0.0%) to $4.28
- Closed at $4.28, +0.00% vs the prior close of $4.28. Day range $4.12–$4.32, opened at $4.25.
- Volume was 1.60M shares, 0.7x its 50-day average of 2.33M.
- Price is +19.0% vs its 50-day average ($3.60) and -9.2% vs its 200-day average ($4.71).
- 52-week range $2.74–$8.59; today's close sits at 26% of that range, 50.2% below the 52-week high.
Oct 6, 2026 — MYGN slides 6.6% to $4.28
- Closed at $4.28, -6.55% vs the prior close of $4.58. Day range $4.22–$4.83, opened at $4.62.
- Volume was 1.80M shares, 0.8x its 50-day average of 2.32M.
- Price is +18.3% vs its 50-day average ($3.62) and -9.4% vs its 200-day average ($4.72).
- 52-week range $2.74–$8.59; today's close sits at 26% of that range, 50.2% below the 52-week high.
Oct 5, 2026 — MYGN rises 0.9% to $4.58, a 1-month high
- Closed at $4.58, +0.88% vs the prior close of $4.54. Day range $4.41–$4.62, opened at $4.51.
- Volume was 2.76M shares, 1.2x its 50-day average of 2.28M.
- Price is +25.8% vs its 50-day average ($3.64) and -3.3% vs its 200-day average ($4.74).
- 52-week range $2.74–$8.59; today's close sits at 31% of that range, 46.7% below the 52-week high.
Oct 2, 2026 — MYGN jumps 11.8% to $4.54, a 1-month high
- Closed at $4.54, +11.82% vs the prior close of $4.06. Day range $4.16–$4.59, opened at $4.16.
- Volume was 2.28M shares, 1.0x its 50-day average of 2.25M.
- Price is +24.0% vs its 50-day average ($3.66) and -4.4% vs its 200-day average ($4.75).
- 52-week range $2.74–$8.59; today's close sits at 31% of that range, 47.1% below the 52-week high.
MYGN latest news & SEC filings
Every SEC filing by or about MYGN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wheeler Benjamin Richard had withheld for taxes 2,555 shares at $4.01 (≈$10.25K) on Sep 21, 2026; now holds 287,193
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sikri Vishal received an award of 257,731 shares on Sep 16, 2026; now holds 351,224
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 4, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $190.70M (prior year $213.10M) (-10.5% vs Jun 30, 2025)
- Net income: -$43.20M (prior year -$330.50M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.46 (prior year -$3.57) (loss narrowed vs Jun 30, 2025)
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade MYGN
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 23, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.07% (largest 11.8%). That is a volatile stock.
- Liquidity: about 1.74M shares (≈$6.92M) trade per day on average.
- 52-week position: $3.98 vs a range of $2.74–$8.59 (21% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 20 open-market buys, 4 sales; latest: Rashmi Kumar sold 15,000 shares on Jun 8, 2026.
- Latest filings: 8-K Oct 9, 2026; 8-K Sep 16, 2026; 10-Q Jul 31, 2026.
- Share count: 95.65M shares outstanding (Jul 28, 2026), +2.8% vs a year earlier.
- Listing: Nasdaq · industry: In Vitro & In Vivo Diagnostic Substances.
MYGN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 4.34 | 4.34 | 3.97 | 3.98 | 1.42M |
| Oct 15, 2026 | 4.20 | 4.42 | 4.11 | 4.35 | 1.07M |
| Oct 14, 2026 | 4.08 | 4.29 | 4.04 | 4.15 | 1.86M |
| Oct 13, 2026 | 4.20 | 4.22 | 4.05 | 4.08 | 1.38M |
| Oct 12, 2026 | 4.30 | 4.32 | 4.19 | 4.20 | 1.38M |
| Oct 9, 2026 | 4.18 | 4.40 | 4.15 | 4.31 | 1.37M |
| Oct 8, 2026 | 4.24 | 4.26 | 4.05 | 4.20 | 2.26M |
| Oct 7, 2026 | 4.25 | 4.32 | 4.12 | 4.28 | 1.60M |
| Oct 6, 2026 | 4.62 | 4.83 | 4.22 | 4.28 | 1.80M |
| Oct 5, 2026 | 4.51 | 4.62 | 4.41 | 4.58 | 2.76M |
| Oct 2, 2026 | 4.16 | 4.59 | 4.16 | 4.54 | 2.28M |
| Oct 1, 2026 | 4.28 | 4.31 | 4.06 | 4.06 | 1.66M |
| Sep 30, 2026 | 4.28 | 4.39 | 4.22 | 4.31 | 1.50M |
| Sep 29, 2026 | 4.26 | 4.37 | 4.22 | 4.23 | 1.60M |
| Sep 28, 2026 | 4.11 | 4.34 | 4.08 | 4.24 | 1.18M |
| Sep 25, 2026 | 4.16 | 4.25 | 4.07 | 4.17 | 1.65M |
| Sep 24, 2026 | 4.00 | 4.26 | 3.97 | 4.14 | 1.96M |
| Sep 23, 2026 | 4.02 | 4.23 | 3.97 | 4.01 | 1.66M |
| Sep 22, 2026 | 3.90 | 4.06 | 3.76 | 4.02 | 2.49M |
| Sep 21, 2026 | 3.93 | 4.04 | 3.87 | 4.01 | 1.89M |
About Myriad Genetics
Myriad Genetics (MYGN) is listed on the Nasdaq and classified by the SEC under “In Vitro & In Vivo Diagnostic Substances”. Its business address is in SALT LAKE CITY, UT. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 899923.
MYGN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Paul Bisaro | Director | Jun 5, 2026 |
| Mark Steven Davis | Director | Jun 5, 2026 |
| Heinrich Dreismann | Director | Jun 5, 2026 |
| Rashmi Kumar | Director | Jun 9, 2026 |
| Lee Nisley Newcomer | Director | Jun 5, 2026 |
| S. Louise Phanstiel | Director | Jun 5, 2026 |
| Samraat S. Raha | President and CEO | Jun 12, 2026 |
| Colleen F Reitan | Director | Jun 5, 2026 |
| Daniel Skovronsky | Director | Jun 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Margaret Ancona | EVP, Strategy & Transformation | Nov 4, 2025 |
| Brian J Donnelly | Chief Commercial Officer | Sep 18, 2026 |
| Jennifer Lynne Fox | Chief Legal Officer | Sep 8, 2026 |
| Kevin Richard Haas | Chief Technology Officer | Mar 16, 2026 |
| Raj Jampa | Chief Technology Officer | Jun 2, 2026 |
| Natalie Munk | Chief Accounting Officer | Oct 24, 2025 |
| Dale Muzzey | Chief Scientific Officer | Apr 15, 2026 |
| Samraat S. Raha | President and CEO | Jun 12, 2026 |
| Vishal Sikri | EVP, Commercial | Sep 17, 2026 |
| Shereen Solaiman | Chief People Officer | Mar 16, 2026 |
| Mark Verratti | Chief Operating Officer | Apr 15, 2026 |
| Benjamin Richard Wheeler | Chief Financial Officer | Sep 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 8, 2026 | Rashmi Kumar | Sale | 15,000 | $4.46 |
| Jun 8, 2026 | Rashmi Kumar | Sale | 15,000 | $4.46 |
| Jun 8, 2026 | Rashmi Kumar | Sale | 15,000 | $4.46 |
| Jun 8, 2026 | Rashmi Kumar | Sale | 15,000 | $4.46 |
| May 14, 2026 | Paul Bisaro | Buy | 7,500 | $3.69 |
| May 14, 2026 | Paul Bisaro | Buy | 7,500 | $3.69 |
| May 14, 2026 | Paul Bisaro | Buy | 7,500 | $3.69 |
| May 14, 2026 | Paul Bisaro | Buy | 7,500 | $3.69 |
| Mar 9, 2026 | Samraat S. Raha | Buy | 40,000 | $5.00 |
| Mar 9, 2026 | Samraat S. Raha | Buy | 40,000 | $5.00 |
| Mar 9, 2026 | Samraat S. Raha | Buy | 40,000 | $5.00 |
| Mar 9, 2026 | Samraat S. Raha | Buy | 40,000 | $5.00 |
| Feb 27, 2026 | S. Louise Phanstiel | Buy | 48,000 | $4.66 |
| Feb 27, 2026 | S. Louise Phanstiel | Buy | 48,000 | $4.66 |
| Feb 27, 2026 | S. Louise Phanstiel | Buy | 48,000 | $4.66 |
MYGN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $824.50M | $-365.90M | -3.95 | $1.80M |
| Dec 31, 2024 | $837.60M | $-127.30M | -1.41 | $-8.70M |
| Dec 31, 2023 | $753.20M | $-263.30M | -3.18 | $-110.90M |
| Dec 31, 2022 | $678.40M | $-112.00M | -1.39 | $-106.30M |
| Dec 31, 2021 | $690.60M | $-27.20M | -0.35 | $18.60M |
Latest balance sheet: total assets $638.90M, total liabilities $335.00M, cash $115.20M (as of Jun 30, 2026).
MYGN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $5.37 |
| May 5, 2026 | 8-K Item 2.02 (results) | $5.03 |
| Feb 23, 2026 | 8-K Item 2.02 (results) | $4.38 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $6.57 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $8.18 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $3.87 |
| May 6, 2025 | 8-K Item 2.02 (results) | $7.27 |
| Feb 24, 2025 | 8-K Item 2.02 (results) | $13.78 |
| Jan 15, 2025 | 8-K Item 2.02 (results) | $13.15 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $17.67 |
| Oct 9, 2024 | 8-K Item 2.02 (results) | — |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · In Vitro & In Vivo Diagnostic Substances
Idexx Laboratories (IDXX)Lantheus (LNTH)Celldex Therapeutics (CLDX)Intellia Therapeutics (NTLA)Neogen (NEOG)QuidelOrtho (QDEL)Achieve Life Sciences (ACHV)Alpha Teknova (TKNO)Q/C Technologies (QCLS)Insight Molecular Diagnostics (IMDX)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on MYGN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.